NCT04685512 (AR0-CORONA) is a Phase 2, PHASE3 clinical trial of tenofovir disoproxil and emtricitabine in Covid19, sponsored by University Hospital, Caen.

Who is sponsoring NCT04685512?

NCT04685512 is sponsored by University Hospital, Caen.

What drugs are being tested in NCT04685512?

Interventions in NCT04685512: tenofovir disoproxil and emtricitabine.

Is NCT04685512 still recruiting?

NCT04685512 is currently completed. Last updated 1 July 2021.

Last reviewed 2021-07-01 · How we verify

NCT04685512: AR0-CORONA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home

Completed Phase 2, PHASE3 Last updated 1 July 2021

What this trial tests

Phase 2, PHASE3 trial testing tenofovir disoproxil and emtricitabine in Covid19 in 60 participants. Completed in 1 May 2021.

Timeline

18 November 2020

Primary endpoint
1 April 2021

1 May 2021

Quick facts

Lead sponsor	University Hospital, Caen
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	60
Start date	18 November 2020
Primary completion	1 April 2021
Estimated completion	1 May 2021
Sites	2 locations across France

Drugs / interventions tested

tenofovir disoproxil and emtricitabine

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

University Hospital, Caen

Who can join

18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

COVID-19 pandemic is currently affecting the globe. To date, there is no effective oral therapy against SARS-CoV2 infection. The investigators propose to test as a repurposing drug combination, a short course of tenofovir disoproxil and emtricitabine (TDF/FTC), as a proof-of-concept randomized open-label study to test its viral efficacy against SARS-CoV2.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment.
Drożdżal S, Rosik J, Lechowicz K, Machaj F, et al · · 2021 · cited 186× · PMID 34991982 · DOI 10.1016/j.drup.2021.100794
Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: A pilot, randomized, open-label phase 2 trial.
Parienti JJ, Prazuck T, Peyro-Saint-Paul L, Fournier A, et al · · 2021 · cited 49× · PMID 34222849 · DOI 10.1016/j.eclinm.2021.100993
Antiviral drug treatment for nonsevere COVID-19: a systematic review and network meta-analysis.
Pitre T, Van Alstine R, Chick G, Leung G, et al · · 2022 · cited 41× · PMID 35878897 · DOI 10.1503/cmaj.220471
Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection.
Zanella I, Zizioli D, Castelli F, Quiros-Roldan E. · · 2021 · cited 33× · PMID 34064831 · DOI 10.3390/ph14050454
Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19.
von Hentig N. · · 2021 · cited 5× · PMID 33660020 · DOI 10.1007/s00228-021-03108-x

Verify or expand the search:

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other University Hospital, Caen trials

Trials by the same sponsor.

NCT07406737 — Feasibility and Outcomes Registry of Lumenless dEfibrillation Leads for Conduction System Pacing · not yet recruiting
NCT06639750 — Respiratory Microbioma and Respiratory Complications After Hematopoietic Stem Cell Transplantion · not yet recruiting
NCT07467031 — Bachstim Registry: a Feasability Study of Bachmann's Area Pacing · not yet recruiting
NCT07477132 — A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 · Phase 4 · not yet recruiting
NCT07520578 — EFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WI · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04685512 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Caen
Last refreshed: 1 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04685512.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing